Engineered deoxyribose-phosphate aldolases
US-11845968-B2 · Dec 19, 2023 · US
Engineered deoxyribose-phosphate aldolases
US12460195B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12460195-B2 |
| Application number | US-202318503542-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 7, 2023 |
| Priority date | Jul 9, 2018 |
| Publication date | Nov 4, 2025 |
| Grant date | Nov 4, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.
First claim
Opening claim text (preview).
We claim: 1 . An engineered deoxyribose-phosphate aldolase comprising a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 2, or a functional fragment thereof, wherein said engineered deoxyribose-phosphate aldolase comprises a substitution in said polypeptide sequence of a methionine residue at position 47 relative to SEQ ID NO: 2, wherein said engineered deoxyribose-phosphate aldolase exhibits at least one improved property compared to the wild-type deoxyribose-phosphate aldolase of SEQ ID NO:2. 2 . The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said polypeptide sequence further comprises at least one substitution or substitution set in said polypeptide sequence at one or more positions relative to SEQ ID NO: 2 selected from 10/66/141/145/156, 2, 6, 9, 10/88/156, 13, 31, 46, 134/141/212, 66, 66/88/112/134/141/143/145/212, 71, 72, 88, 94, 102, 104, 112, 116, 133, 133/173/204/235/236, 134, 147, 173, 184, 189, 197, 203, 204, 207, 226, 235, 235/236, and 236. 3 . The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said polypeptide sequence further comprises at least one substitution or substitution set in said polypeptide sequence at one or more positions relative to SEQ ID NO: 2 selected from 2, 2/6/10/66/88/102/184/235/236, 2/6/102/141/203/235, 2/10/102/235/236, 2/66/71/141/184/203/235/236, 2/71/88/203/235/236, 2/71/141/197/235/236, 2/88/141/235/236, 2/203/235/236, 5, 6/203/235/236, 9, 10/66/184/197/236, 10/66/235/236, 10/71/184/203/235/236, 13, 13/46, 13/46/66/94, 13/46/66/94/184/204, 13/46/66/133/134/184, 13/46/66/184, 13/46/112/134/184, 13/46/133/184, 13/66/94, 13/66/94/184, 13/66/112/133/134/184/204, 13/66/112/133/134/204, 13/66/112/184, 13/66/133/134/184/204, 13/66/184/204, 13/94/133/184, 13/94/184, 13/94/184/204, 13/133/134/184, 13/133/134/204, 13/134/204, 13/184, 27, 40, 46/66/94/112, 46/66/112/133/134/184, 46/66/133/134, 46/66/133/184/197, 46/66/133/197, 46/66/134/184/197/204, 46/66/184, 46/112/133, 46/112/133/134/204, 46/133/204, 46/197/204, 66/71/88/203/235/236, 66/71/141/184, 66/88/184/235, 66/88/203/235/236, 66/141/235/236, 66/184/197/203/235/236, 66/184/197/236, 71/88/184/203/235, 71/88/184/203/236, 71/141/184/203/235, 71/184, 71/184/197/236, 71/184/235, 71/184/236, 88/102/141/235/236, 88/203/235/236, 88/235/236, 102/184/197/235/236, 102/203/235/236, 141/184, 141/184/236, 184/236, 203/235, 203/235/236, 203/236, 235/236, 62, 66, 66/88/102/184/197/203/235/236, 66/88/197, 66/88/235, 66/88/235/236, 66/94, 66/94/112/133/184, 66/94/112/184/204, 66/102/184/235/236, 66/112/133/134/197, 66/112/133/197, 66/112/134/197, 66/112/184, 66/133/184, 66/133/197, 66/184, 66/197/203/235, 84, 88, 88/102/141/184/235/236, 88/184, 88/184/197/203/235/236, 88/184/197/235/236, 88/184/203/235, 88/184/236, 88/197/235/236, 88/236, 94/112/184/197, 94/133/184, 96, 102/141/203, 102/184/203/236, 102/184/236, 102/197/235, 112, 112/133/134, 112/133/184/204, 112/134/197, 114, 115, 120, 127, 132, 133, 133/134/184, 141/184/203/235/236, 141/184/235, 141/197, 141/203/235/236, 141/236, 146, 148, 184, 184/203, 184/203/235, 184/203/236, 184/235/236, 184/236, 197/235, 203/235/236, 203/236, 204, 218, 235, 235/236, and 236. 4 . The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said polypeptide sequence further comprises at least one substitution or substitution set in said polypeptide sequence relative to SEQ ID NO: 2 at one or more positions selected from 71/88/94/133, 71/133, and 133. 5 . The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence that is at least 95% identical to the sequence of at least one engineered deoxyribose-phosphate aldolase variant set forth in the even numbered sequences of SEQ ID NOS: 4-478. 6 . The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence forth in the even numbered sequences of SEQ ID NOS: 4, 6, 8, 124, and 140-326, 334, 338, 342, 344, 348-352, 356, 358, 362, 374, 376, 386, 388, 392-396, 400, 402, 406-410, 418, 420-424, 428, 430, 434-440, 448, 450, 454, 456, 460-464, 470, and 472. 7 . The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said improved property comprises improved activity on a substrate. 8 . The engineered deoxyribose-phosphate aldolase of claim 7 , wherein said substrate comprises R-2-ethynyl-glyceraldehyde. 9 . The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said improved property comprises improved thermostability. 10 . The engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase is purified. 11 . A composition comprising at least one engineered deoxyribose-phosphate aldolase provided in claim 1 .
Assignees
Inventors
Classifications
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
Deoxyribose-phosphate aldolase (4.1.2.4) · CPC title
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
- C12N9/88Primary
Lyases (4.) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12460195B2 cover?
- The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.
- Who is the assignee on this patent?
- Codexis Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/88. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).